In a new study, a Yale-led research team uncovers how a very low calorie diet can rapidly reverse type 2 diabetes in animal models. If confirmed in people, the insight provides potential new drug targets for treating this common chronic disease, said the researchers.
The study is published in Cell Metabolism.
One in three Americans will develop type 2 diabetes by 2050, according to recent projections by the Center for Disease Control and Prevention. Reports indicate that the disease goes into remission in many patients who undergo bariatric weight-loss surgery, which significantly restricts caloric intake prior to clinically significant weight loss. The Yale-led team’s study focused on understanding the mechanisms by which caloric restriction rapidly reverses type 2 diabetes.
The research team investigated the effects of a very low calorie diet (VLCD), consisting of one-quarter the normal intake, on a rodent model of type 2 diabetes. Using a novel stable (naturally occurring) isotope approach, which they developed, the researchers tracked and calculated a number of metabolic processes that contribute to the increased glucose production by the liver. The method, known as PINTA, allowed the investigators to perform a comprehensive set of analyses of key metabolic fluxes within the liver that might contribute to insulin resistance and increased rates of glucose production by the liver — two key processes that cause increased blood-sugar concentrations in diabetes.
Using this approach the researchers pinpointed three major mechanisms responsible for the VLCD’s dramatic effect of rapidly lowering blood glucose concentrations in the diabetic animals. In the liver, the VLCD lowers glucose production by: 1) decreasing the conversion of lactate and amino acids into glucose; 2) decreasing the rate of liver glycogen conversion to glucose; and 3) decreasing fat content, which in turn improves the liver’s response to insulin. These positive effects of the VLCD were observed in just three days.
“Using this approach to comprehensively interrogate liver carbohydrate and fat metabolism, we showed that it is a combination of three mechanisms that is responsible for the rapid reversal of hyperglycemia following a very low calorie diet,” said senior author Gerald I. Shulman, M.D., the George R. Cowgill Professor of Medicine and Cellular and Molecular Physiology and an investigator at the Howard Hughes Medical Institute.
The next step for the researchers will be to confirm whether the findings can be replicated in type 2 diabetic patients undergoing either bariatric surgery or consuming very low calorie diets. His team has already begun applying the PINTA methodology in humans.
“These results, if confirmed in humans, will provide us with novel drug targets to more effectively treat patients with type 2 diabetes,” Shulman said.
The Latest on: Type 2 diabetes
- Type 2 diabetes: Study identifies new predictor putting people at ‘high risk’ of diabeteson May 17, 2022 at 7:29 am
DIABETES rates have risen sharply in recent years, and obesity is seen as the main contributor to this crisis. But sometimes, diabetes can develop in conjunction with other underlying conditions that ...
- Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022on May 17, 2022 at 5:00 am
Fractyl Health will share new data in an oral presentation during the 2022 Digestive Disease Week meeting being held May 21-24, 2022, in San Diego, CA ...
- FDA: Newly-approved treatment for type 2 diabetes outperforms older therapieson May 16, 2022 at 5:53 pm
STATEN ISLAND, N.Y. — The United States Food and Drug Administration (FDA) late last week said it had approved a new drug to help improve blood sugar regulation in people with type 2 diabetes.
- Artery stiffness may predict Type 2 diabetes risk better than BP and standard risk factorson May 16, 2022 at 2:00 am
Arterial stiffness was a better predictor of future risk of Type 2 diabetes than blood pressure, and people with a combination of high blood pressure and stiffer arteries had the highest risk of ...
- FDA Approves Mounjaro, a Novel Once-a-Week Medication to Treat Type 2 Diabeteson May 15, 2022 at 9:00 pm
The U.S. Food and Drug Administration (FDA) has Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes (T2D), as an addition to di ...
- Patients With Type 2 Diabetes and CKD Face Poor COVID Outcomeson May 15, 2022 at 2:49 pm
SAN DIEGO -- Certain factors were highly predictive of severe COVID illness in hospitalized patients who had type 2 diabetes (T2D) and chronic kidney disease (CKD), a researcher reported. In a ...
- U.S. FDA approves Eli Lilly's treatment for type 2 diabeteson May 13, 2022 at 6:03 pm
The U.S. Food & Drug Administration said on Friday it had approved Eli Lilly's injected drug tirzepatide, which has the brand name Mounjaro, to help improve blood sugar control in adults with type 2 ...
- 'Twincretin' Tirzepatide Gets FDA Approval for Type 2 Diabeteson May 13, 2022 at 4:30 pm
Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also express concern about cost and patient accessibility.
- FDA approves tirzepatide: A potent new drug for type 2 diabeteson May 13, 2022 at 2:28 pm
Today, the Food and Drug Administration (FDA) has approved tirzepatide, a new first-in-class drug for type 2 diabetes.
- FDA Approves New Drug Tirzepatide for People with Type 2 Diabeteson May 13, 2022 at 6:20 am
Share on Pinterest Experts say a new drug shows promise for helping people with type 2 diabetes manage their blood glucose levels. Fertnig/Getty Images A new drug to treat type 2 diabetes has received ...
via Google News and Bing News